These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1061 related articles for article (PubMed ID: 34367132)

  • 1. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
    Lin A; Gu T; Hu X; Zhang J; Luo P
    J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
    Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
    Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma.
    Lin A; Xu W; Luo P; Zhang J
    Front Pharmacol; 2021; 12():721181. PubMed ID: 34721019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To explore the prognostic characteristics of colon cancer based on tertiary lymphoid structure-related genes and reveal the characteristics of tumor microenvironment and drug prediction.
    Wang Z; Niu D
    Sci Rep; 2024 Jun; 14(1):13555. PubMed ID: 38867070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
    Wang Z; Wang C; Lin S; Yu X
    Front Oncol; 2021; 11():725292. PubMed ID: 34513703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
    Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
    Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification prognosis-associated immune genes in colon adenocarcinoma.
    Miao Y; Wang J; Ma X; Yang Y; Mi D
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33140821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prognostic Model Based on the Immune-related Genes in Colon Adenocarcinoma.
    Sun YL; Zhang Y; Guo YC; Yang ZH; Xu YC
    Int J Med Sci; 2020; 17(13):1879-1896. PubMed ID: 32788867
    [No Abstract]   [Full Text] [Related]  

  • 10. Investigating gene signatures associated with immunity in colon adenocarcinoma to predict the immunotherapy effectiveness using NFM and WGCNA algorithms.
    Liang W; Yang X; Li X; Wang P; Zhu Z; Liu S; Xu D; Zhi X; Xue J
    Aging (Albany NY); 2024 May; 16(9):7596-7621. PubMed ID: 38742936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mutational pattern of homologous recombination-related (HRR) genes in Chinese colon cancer and its relevance to immunotherapy responses.
    Zhou P; Wu X; Chen H; Hu Y; Zhang H; Wu L; Yang Y; Mao B; Wang H
    Aging (Albany NY); 2020 Dec; 13(2):2365-2378. PubMed ID: 33318301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of PI4K2A predicted poor prognosis of colon adenocarcinoma (COAD) and correlated with immunity.
    Huang X; Cao Y; Bao P; Zhu B; Cheng Z
    Cancer Med; 2023 Jan; 12(1):837-851. PubMed ID: 35634680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma.
    Liu R; Liang W; Hua Q; Wu L; Wang X; Li Q; Zhong F; Li B; Qiu Z
    Front Immunol; 2022; 13():819515. PubMed ID: 35251000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.
    Niu Y; Lin A; Luo P; Zhu W; Wei T; Tang R; Guo L; Zhang J
    Front Pharmacol; 2020; 11():1213. PubMed ID: 32903385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Sun Y; Li L; Yao W; Liu X; Yang Y; Ma B; Xue D
    Front Genet; 2021; 12():762160. PubMed ID: 34795697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.